WO2012136813A9 - Agents pour un diagnostic par radar médical - Google Patents

Agents pour un diagnostic par radar médical Download PDF

Info

Publication number
WO2012136813A9
WO2012136813A9 PCT/EP2012/056363 EP2012056363W WO2012136813A9 WO 2012136813 A9 WO2012136813 A9 WO 2012136813A9 EP 2012056363 W EP2012056363 W EP 2012056363W WO 2012136813 A9 WO2012136813 A9 WO 2012136813A9
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
agents
radar
medical radar
medical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2012/056363
Other languages
English (en)
Other versions
WO2012136813A2 (fr
WO2012136813A3 (fr
Inventor
Jo Klaveness
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitetet i Oslo
Original Assignee
Universitetet i Oslo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitetet i Oslo filed Critical Universitetet i Oslo
Publication of WO2012136813A2 publication Critical patent/WO2012136813A2/fr
Publication of WO2012136813A3 publication Critical patent/WO2012136813A3/fr
Publication of WO2012136813A9 publication Critical patent/WO2012136813A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/0507—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves using microwaves or terahertz waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0404—X-ray contrast preparations containing barium sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
    • A61K49/105—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA the metal complex being Gd-DTPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Acoustics & Sound (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

La présente invention porte sur l'utilisation d'agents de contraste en imagerie à base de radar, en particulier en imagerie médicale. L'invention porte également sur l'utilisation d'agents de contraste dans le diagnostic de différentes maladies utilisant une technologie à base de radar. L'invention porte également sur un appareil pour imagerie à base de radar comprenant un agent de contraste.
PCT/EP2012/056363 2011-04-07 2012-04-05 Agents pour un diagnostic par radar médical Ceased WO2012136813A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20110544 2011-04-07
NO20110544 2011-04-07

Publications (3)

Publication Number Publication Date
WO2012136813A2 WO2012136813A2 (fr) 2012-10-11
WO2012136813A3 WO2012136813A3 (fr) 2013-01-17
WO2012136813A9 true WO2012136813A9 (fr) 2013-03-14

Family

ID=45998277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/056363 Ceased WO2012136813A2 (fr) 2011-04-07 2012-04-05 Agents pour un diagnostic par radar médical

Country Status (1)

Country Link
WO (1) WO2012136813A2 (fr)

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032567A (en) 1972-02-16 1977-06-28 Schering Aktiengesellschaft Triiodoisophthalic acid monoamino acid amides, process for the preparation thereof, and use thereof as x-ray contrast media
US3908657A (en) 1973-01-15 1975-09-30 Univ Johns Hopkins System for continuous withdrawal of blood
DE2628517C2 (de) 1976-06-23 1985-02-21 Schering AG, 1000 Berlin und 4709 Bergkamen Dicarbonsäure-bis(3,5-dicarbamoyl-2,4,6-trijodanilid)-Verbindungen, Verfahren zu ihrer Herstellung und Röntgenkontrastmittel
US4125599A (en) 1976-08-19 1978-11-14 Mallinckrodt, Inc. X-ray contrast agents
CH626873A5 (fr) 1977-03-28 1981-12-15 Bracco Ind Chimica Spa
NL7905354A (nl) 1978-07-14 1980-01-16 Schering Ag Als roentgen-contrastmiddelen bruikbare trijoodbenzonitril-derivaten.
DE2852094A1 (de) 1978-11-30 1980-06-12 Schering Ag Neue roentgenkontrastmittel
DE2909439A1 (de) 1979-03-08 1980-09-18 Schering Ag Neue nichtionische roentgenkontrastmittel
IT1193211B (it) 1979-08-09 1988-06-15 Bracco Ind Chimica Spa Derivati dell'acido 2,4,6-triiodo-isoftalico,metodo per la loro preparazione e mezzi di contrasto che li contengono
IT1207226B (it) 1979-08-09 1989-05-17 Bracco Ind Chimica Spa Derivati dell'acido 2,4,6-triiodo-isoftalico, metodo per la loro preparazione e mezzi di contrasto che li contengono.
DE3038853A1 (de) 1980-10-10 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue n-hydroxy-alkylierte dicarbonsaeure-bis-(3,5-dicarbamoyl-2,4,6-trijodanilide), deren herstellung und diese enthaltende roentgenkonstrastmittel (ii)
DE3044814A1 (de) 1980-11-25 1982-07-08 Schering Ag, 1000 Berlin Und 4619 Bergkamen Unsymmetrisch substituierte dicarbonsaeure-bis-(2,4,6-trijod-anilide), deren herstellung und diese enthaltende roentgenkontrastmittel
US5560903A (en) 1981-07-24 1996-10-01 Schering Aktiengesellschaft Method of enhancing paramagnetism in chelates for MRI
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
DE3150916A1 (de) 1981-12-18 1983-06-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen N-hydroxyaethylierte 2,4,6-trijodaminoisiophthalsaeure-bis- trihydroxybutylamide, deren herstellung und diese enthaltende roentgenkontrastmittel"
US4396598A (en) 1982-01-11 1983-08-02 Mallinckrodt, Inc. Triiodoisophthalamide X-ray contrast agent
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US5204086A (en) 1982-10-01 1993-04-20 Nycomed Imaging As X-ray contrast agent
ATE20733T1 (de) 1982-11-08 1986-08-15 Nyegaard & Co As Roentgenkontrastmittel.
US5141738A (en) 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
DE3324235A1 (de) 1983-07-01 1985-01-10 Schering AG, 1000 Berlin und 4709 Bergkamen Neue komplexbildner, komplexe und komplexsalze
US5618514A (en) 1983-12-21 1997-04-08 Nycomed Imaging As Diagnostic and contrast agent
MX174467B (es) 1986-01-23 1994-05-17 Squibb & Sons Inc 1,4,7-triscarboximetil-1,4,7,10-tetraazaciclodo decano substituido en 1 y compuestos analogos
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
US5102652A (en) 1986-07-03 1992-04-07 Advanced Magnetics Inc. Low molecular weight carbohydrates as additives to stabilize metal oxide compositions
US5160726A (en) 1990-02-15 1992-11-03 Advanced Magnetics Inc. Filter sterilization for production of colloidal, superparamagnetic MR contrast agents
US4827945A (en) 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5262176A (en) 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
US5132409A (en) 1987-01-12 1992-07-21 Bracco Industria Chimica S.P.A. Macrocyclic chelating agents and chelates thereof
DE3731542A1 (de) 1987-09-17 1989-03-30 Schering Ag Neue dicarbonsaeure-bis(3,5-dicarbamoyl-2,4,6-triiod-anilide), verfahren zu deren herstellung sowie diese enthaltende roentgenkontrastmittel
DE3739098A1 (de) 1987-11-16 1989-05-24 Schering Ag Neue substituierte dicarbonsaeure-bis(3,5-dicarbamoyl-2,4,6- trijod-anilide), verfahren zu deren herstellung sowie diese enthaltende roentgenkontrastmittel
US5425366A (en) 1988-02-05 1995-06-20 Schering Aktiengesellschaft Ultrasonic contrast agents for color Doppler imaging
DE58908194D1 (de) 1988-02-05 1994-09-22 Schering Ag Ultraschallkontrastmittel, verfahren zu deren herstellung und deren verwendung als diagnostika und therapeutika.
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
US5030956A (en) 1989-04-25 1991-07-09 Murphy Quentin M Radar tomography
JP2726520B2 (ja) 1989-10-20 1998-03-11 名糖産業株式会社 有機磁性複合体
US5232685A (en) 1989-11-03 1993-08-03 Schering Aktiengesellschaft Nonionic x-ray contrast medium with high iodine content
DE3937118A1 (de) 1989-11-03 1991-05-08 Schering Ag Nichtionische roentgenkontrastmittel mit hohem jodgehalt
US5614638A (en) 1989-11-29 1997-03-25 Bracco International B.V. Nonionic radiographic contrast agents
US5191120A (en) 1989-12-13 1993-03-02 Mallinckrodt Medical, Inc. Process for preparing nonionic X-ray contrast agents
US5075502A (en) 1989-12-13 1991-12-24 Mallinckrodt, Inc. Nonionic x-ray contrast agents, compositions and methods
US6146657A (en) 1989-12-22 2000-11-14 Imarx Pharmaceutical Corp. Gas-filled lipid spheres for use in diagnostic and therapeutic applications
US6551576B1 (en) 1989-12-22 2003-04-22 Bristol-Myers Squibb Medical Imaging, Inc. Container with multi-phase composition for use in diagnostic and therapeutic applications
US5656211A (en) 1989-12-22 1997-08-12 Imarx Pharmaceutical Corp. Apparatus and method for making gas-filled vesicles of optimal size
US5922304A (en) 1989-12-22 1999-07-13 Imarx Pharmaceutical Corp. Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
IN172208B (fr) 1990-04-02 1993-05-01 Sint Sa
US6613306B1 (en) 1990-04-02 2003-09-02 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US7083778B2 (en) 1991-05-03 2006-08-01 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
DE4035760A1 (de) 1990-11-08 1992-05-14 Schering Ag Mono-n-substituierte 1,4,7,10-tetraazacyclododecan-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5019371A (en) 1990-11-21 1991-05-28 Mallinckrodt Medical, Inc. Novel x-ray contrast agents, compositions and methods
US5356613A (en) 1991-03-18 1994-10-18 Mallinckrodt Medical, Inc. X-ray contrast agents, compositions and methods
GB9106686D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
DK0586524T3 (fr) 1991-06-03 1997-05-20 Nycomed Imaging As
EP0529175B1 (fr) 1991-07-22 1995-08-09 BRACCO International B.V. Conjugés chélatés aux métaux paramagnétiques, pour ciblage
US5409688A (en) 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
GB9200387D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200391D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
GB9200388D0 (en) 1992-01-09 1992-02-26 Nycomed As Improvements in or relating to contrast agents
US5648062A (en) 1992-01-09 1997-07-15 Nycomed Imaging As Contrast agents consisting of galactose particles
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them
US5674468A (en) 1992-03-06 1997-10-07 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
US5464696A (en) 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
WO1994009703A1 (fr) 1992-11-02 1994-05-11 Drexel University Melanges de microbulles stabilisees par un tensio-actif, et leurs procedes de preparation et d'utilisation
IL110391A (en) 1993-07-30 1998-12-06 Zambon Spa Process for the crystallization of iopamidol
GB9318550D0 (en) 1993-09-07 1993-10-20 Nycomed Salutar Inc Chelants
US6217849B1 (en) 1993-09-29 2001-04-17 Bracco Research S.A. Liposome suspensions as blood pool imaging contrast agents
PT682530E (pt) 1993-12-15 2003-06-30 Bracco Research Sa Misturas de gases uteis como meios de contraste para ultrassons
GB9402867D0 (en) 1994-02-15 1994-04-06 Nycomed Imaging As Improvements in or relating to contrast agents
NO940711D0 (no) 1994-03-01 1994-03-01 Nycomed Imaging As Preparation of gas-filled microcapsules and contrasts agents for diagnostic imaging
DE69527194T2 (de) 1994-03-28 2003-02-06 Daiichi Pharmaceutical Co., Ltd. Liposomen enthaltend ein röntgen- oder ultraschallkontrastmittel
US6310243B1 (en) 1994-09-23 2001-10-30 Nycomed Imaging As Iodinated x-ray contrast media
GB9419203D0 (en) 1994-09-23 1994-11-09 Nycomed Innovation Ab Contrast media
GB9419206D0 (en) 1994-09-23 1994-11-09 Nycomed Innovation Ab Contrast media
US5702722A (en) 1994-09-30 1997-12-30 Bracco Research S.A. Liposomes with enhanced entrapment capacity, method and use
IT1271107B (it) 1994-11-29 1997-05-26 Zambon Spa Processo per la preparazione di un intermedio utile nella sintesi di composti organici
IL116328A (en) 1994-12-16 1999-09-22 Bracco Research Sa Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
WO2004073750A1 (fr) 1995-06-07 2004-09-02 Harald Dugstad Ameliorations relatives a des agents de contraste
US6521211B1 (en) 1995-06-07 2003-02-18 Bristol-Myers Squibb Medical Imaging, Inc. Methods of imaging and treatment with targeted compositions
KR100270411B1 (ko) 1995-09-08 2000-11-01 네니드 토모브-그리소고노 (s)-n,n'-비스[2-히드록시-1-(히드록시메틸)에틸-5-[(2-히드록시-1-옥소프로필)아미노]-2,4,6-트리요오도-1,3-벤젠디카복사미드의물로부터의결정화방법
GB9600427D0 (en) 1996-01-10 1996-03-13 Nycomed Imaging As Contrast media
US6165442A (en) 1996-02-19 2000-12-26 Nycomed Imaging As Thermally stabilized ultrasound contrast agent
ES2197986T3 (es) 1996-02-19 2004-01-16 Amersham Health As Mejoras introducidas en o relacionadas con agentes de contraste.
NZ334365A (en) 1996-08-02 1999-10-28 Nycomed Imaging As Use of a contrast agent comprising microbubbles of biocompatible gas stabilised by opsonisable amphiphilic material for ultrasound imaging of the liver
WO1998008899A1 (fr) 1996-08-30 1998-03-05 Meito Sangyo Kabushiki Kaisha Composite contenant un derive de polysaccharide et un oxyde metallique magnetique
US6331289B1 (en) 1996-10-28 2001-12-18 Nycomed Imaging As Targeted diagnostic/therapeutic agents having more than one different vectors
ATE314097T1 (de) 1996-10-28 2006-01-15 Amersham Health As Kontrastmittel
AU733495B2 (en) 1996-10-28 2001-05-17 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
ES2206689T3 (es) 1996-10-28 2004-05-16 Amersham Health As Agentes de contraste.
US6054118A (en) 1997-01-22 2000-04-25 Nycomed Imaging As Contrast agents comprising two types of gas-containing microparticles
GB9708240D0 (en) 1997-04-23 1997-06-11 Nycomed Imaging As Improvements in or relating to contrast agents
GB9712524D0 (en) * 1997-06-16 1997-08-20 Nycomed Imaging As Method
US6045777A (en) 1997-06-30 2000-04-04 Acusphere, Inc. Method for enhancing the echogenicity and decreasing the attenuation of microencapsulated gases
US6548047B1 (en) 1997-09-15 2003-04-15 Bristol-Myers Squibb Medical Imaging, Inc. Thermal preactivation of gaseous precursor filled compositions
IT1302200B1 (it) 1998-09-11 2000-07-31 Dibra Spa PROCESSO PER LA PREPARAZIONE DELLA S-N,N'-BIS°2-IDROSSI-1-(IDROSSIMETIL)ETILé-5-°(2-IDROSSI-1-
EP1140211A1 (fr) 1998-10-12 2001-10-10 Mallinckrodt Inc. Agents de contraste pour ultrasons
IT1303797B1 (it) 1998-11-27 2001-02-23 Bracco Spa Processo per la preparazione di n,n'-bis(2,3-diidrossipropil)-5-((idrossiacetil)metilammino)-2,4,6-triiodo-1,3-benzendicarbossammide.
US7807137B1 (en) 1998-12-22 2010-10-05 University Of Puerto Rico Iron-based contrast agent
US6803485B2 (en) 1999-02-26 2004-10-12 Bracco Imaging S.P.A. Process for the preparation of iopamidol
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
US6406680B1 (en) 1999-09-17 2002-06-18 Nycomed Imaging As X-ray contrast agents
US7745590B1 (en) 2001-11-13 2010-06-29 University Of Utah Research Foundation Degradable macromolecular magnetic resonance imaging contrast agents and methods thereof
US7010339B2 (en) 2002-07-29 2006-03-07 The United States Of America As Represented By The Secretary Of The Navy Hybrid lidar-radar for medical diagnostics
EP1598082A4 (fr) 2003-02-27 2008-11-12 Univ Kyushu Nat Univ Corp Produit de contraste pour irm
US7725150B2 (en) 2003-06-04 2010-05-25 Lifewave, Inc. System and method for extracting physiological data using ultra-wideband radar and improved signal processing techniques
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US7588751B2 (en) 2004-07-21 2009-09-15 Konica Minolta Medical & Graphic, Inc. Liposome-containing radiographic contrast medium and preparation method thereof
EP1762563A1 (fr) 2005-09-13 2007-03-14 BRACCO IMAGING S.p.A. Procédé de préparation d'agents de contraste
US7767196B2 (en) 2005-11-21 2010-08-03 The University Of Hong Kong Optimized relaxivity and specificity hepatobiliary MRI contrast agent
NO20055702D0 (no) 2005-12-02 2005-12-02 Amersham Health As Contrast agents
US7892520B2 (en) 2006-07-31 2011-02-22 The Hong Kong University Of Science And Technology Solid-state synthesis of iron oxide nanoparticles
BRPI0814811A2 (pt) 2007-07-12 2015-02-03 Ge Healthcare As Composto, agente, método, e composição de diagnóstico, uso de um composto, e, método de formação de imagem
DE102008006711A1 (de) 2008-01-30 2009-08-13 Siemens Aktiengesellschaft Medizinische Diagnose- oder Therapieeinheit und Verfahren zur Verbesserung von Untersuchungs- bzw. Behandlungsabläufen mit einer medizinischen Diagnose- oder Therapieeinheit
DE102008064400A1 (de) * 2008-06-02 2009-12-03 Rohde & Schwarz Gmbh & Co. Kg Mikrowellenuntersuchung mit einem Kontrastmittel
WO2010124117A2 (fr) 2009-04-22 2010-10-28 Lifewave, Inc. Dispositif et procédés de contrôle foetal
DE102009021232B4 (de) 2009-05-14 2017-04-27 Siemens Healthcare Gmbh Patientenliege, Verfahren für eine Patientenliege und bildgebendes medizinisches Gerät
US7754920B1 (en) 2009-07-21 2010-07-13 Ge Healthcare As Solvent reduction in crystallisation of intermediate for non-ionic X-ray contrast agents
GB0920839D0 (en) * 2009-11-27 2010-01-13 Univ Bristol Contrast agents for medical imaging

Also Published As

Publication number Publication date
WO2012136813A2 (fr) 2012-10-11
WO2012136813A3 (fr) 2013-01-17

Similar Documents

Publication Publication Date Title
EP2563228B8 (fr) Couplage d'une sonde à ultrasons à la peau
WO2012149299A3 (fr) Procédés de traitement du cancer et de maladies inflammatoires au moyen de céréblon en tant que prédicteur
EP2696771B8 (fr) Caractérisation vasculaire utilisant l'imagerie ultrasonore
EP2649944A4 (fr) Dispositif de diagnostic par ultrasons
WO2011161226A3 (fr) Nouvelle formulation d'anticorps
SG11201401921YA (en) Formulations for the treatment of diabetes
FR2972915B1 (fr) Systeme d'imagerie medicale multiplan
IL221412A (en) Urine drug delivery system
WO2013089882A3 (fr) Fusions de gènes récurrentes dans le cancer du sein
EP2667237A4 (fr) Équipement et procédé pour l'exploration, l'établissement de diagnostic ou l'aide à l'établissement de diagnostic et le traitement de problèmes fonctionnels de la vue
WO2013052647A3 (fr) Formulations et utilisations d'agonistes sélectifs du récepteur de l'acide rétinoïque
WO2012158780A3 (fr) Signature du cancer du poumon
WO2012109466A3 (fr) Arn long non codant spry4-it1 comme agent de diagnostic et thérapeutique
EP2663964A1 (fr) Système d'imagerie tomographique à deux énergies
WO2012131001A3 (fr) Coussin pour interface patient
EP2990040A4 (fr) Agent thérapeutique pour maladie du fond de l'oeil
IL229607B (en) A method for diagnosing Gaucher's disease
IL230959A0 (en) A device for the treatment of eye disease
MX336369B (es) Uso de acido elagico como agentes anticaspa.
WO2012136813A3 (fr) Agents pour un diagnostic par radar médical
EP2547395B8 (fr) Procédé de fabrication d'une electrode a usage médical et électrode obtenue par la mise en oeuvre de ce procédé
EP2887068B8 (fr) Procédé pour améliorer le diagnostic d'infections invasives par Candida via la détection d'une protéine FBA1
김영석 Transabdominal Ultrasound (TAUS)
WO2011124861A3 (fr) Utilisation de composés oligosaccharides dérivés du xanthane comme agent énergisant
GB201009091D0 (en) Compounds for the treatment of clostridium difficile-associated disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12715900

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12715900

Country of ref document: EP

Kind code of ref document: A2